RTP Mobile Logo
Oncology Nursing Update Breast Cancer, Issue 1, 2013
Released November 2013

Featuring interviews with Ms Carrie Tompkins Stricker and Dr Sara A Hurvitz. (Audio Content)

CE Disclosures and Faculty Information

    Breast cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern, with more than 230,000 new cases and 40,000 deaths from metastatic breast cancer expected in the United States during 2013. Patients with estrogen and/or progesterone receptor-positive (ER/PR-positive) and/or HER2-positive disease account for the majority of patients with metastatic breast cancer, and recently the emergence of new and critical data sets has seemingly transformed clinical management on an almost daily basis. To provide oncology nurses with therapeutic strategies to address the disparate needs of these patients with metastatic breast cancer, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses with expertise in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with ER/PR-positive and/or HER2-positive metastatic breast cancer.

      • Describe the influence of tumor phenotypes in tailoring systemic treatment decisions.
      • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of metastatic breast cancer, including endocrine agents, chemotherapy regimens and biologic treatments.
      • Develop a plan to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
      • Recognize the recent FDA approvals of ado-trastuzumab emtansine (T-DM1), pertuzumab and everolimus, and identify clinical situations for which these agents may be appropriate therapeutic options.
      • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Tompkins StrickerStock Ownership: On Q Health Inc. Dr HurvitzContracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Travel: Novartis Pharmaceuticals Corporation.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    November 2013
    Expiration date: November 2014

Acknowledge and close

Listen to audio:
Oncology Nursing Update Breast Cancer, Issue 1, 2013
Released November 2013

Featuring interviews with Ms Carrie Tompkins Stricker and Dr Sara A Hurvitz. (Audio Content)

Read print: